Manganese Superoxide Dismutase Dysfunction and the Pathogenesis of Kidney Disease

Munehiro Kitada1,2,*, Jing Xu1, Yoshio Ogura1, Itaru Monno1 and Daisuke Koya1,2

1 Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Japan, 2 Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Japan

The mitochondria are a major source of reactive oxygen species (ROS). Superoxide anion (O$_2$$^•\text{-}$) is produced by the process of oxidative phosphorylation associated with glucose, amino acid, and fatty acid metabolism, resulting in the production of adenosine triphosphate (ATP) in the mitochondria. Excess production of reactive oxidants in the mitochondria, including O$_2$$^•\text{-}$, and its by-product, peroxynitrite (ONOO$^-$), which is generated by a reaction between O$_2$$^•\text{-}$ with nitric oxide (NO$^*$), alters cellular function via oxidative modification of proteins, lipids, and nucleic acids. Mitochondria maintain an antioxidant enzyme system that eliminates excess ROS; manganese superoxide dismutase (Mn-SOD) is one of the major components of this system, as it catalyzes the first step involved in scavenging ROS. Reduced expression and/or the activity of Mn-SOD results in diminished mitochondrial antioxidant capacity; this can impair the overall health of the cell by altering mitochondrial function and may lead to the development and progression of kidney disease. Targeted therapeutic agents may protect mitochondrial proteins, including Mn-SOD against oxidative stress-induced dysfunction, and this may consequently lead to the protection of renal function. Here, we describe the biological function and regulation of Mn-SOD and review the significance of mitochondrial oxidative stress concerning the pathogenesis of kidney diseases, including chronic kidney disease (CKD) and acute kidney injury (AKI), with a focus on Mn-SOD dysfunction.

Keywords: manganese superoxide dismutase, acute kidney injury, chronic kidney disease, mitochondria, peroxynitrite, posttranslational modification

INTRODUCTION

The prevalence of chronic kidney disease (CKD) has been increasing worldwide (Eckardt et al., 2013). CKD is characterized by the gradual loss of renal function over a period of months to years, ultimately leading to end-stage renal disease (ESRD). CKD has also been recognized as an independent risk factor for cardiovascular disease (CVD) (Go et al., 2004; Gansevoort et al., 2013). In contrast, acute kidney injury (AKI), also known as acute renal failure, is defined as the sudden and rapid loss of renal function, often within 48 h (KDIGO, 2012). AKI is closely associated with the increased risk of developing CKD, and progression is directly dependent on the severity of AKI (Fiorentino et al., 2018). Therefore, to suppress these outcomes, it will be necessary to have a...
better understanding of the underlying fundamental mechanisms related to progression and onset of both CKD and AKI.

Reactive oxygen species (ROS) can damage cellular proteins, lipids, and DNA, ultimately leading to cellular dysfunction (Wang et al., 2018). Mitochondria are the major source of endogenous ROS, which depends directly on the metabolic and redox state of the mitochondria. Metabolic state refers to the efficiency of electron transfer from nutrients to molecular oxygen (O$_2$). Electrons that are leaked from the respiratory chain react with O$_2$ to produce superoxide anions (O$_2$$^•−$). Mitochondria have ROS scavenging systems via which O$_2$$^•−$ is converted to H$_2$O$_2$ by the actions of superoxide dismutase (SOD), including Cu/Zn-SOD and manganese superoxide dismutase (Mn-SOD) (Mailloux, 2015; Kim et al., 2017; Wang et al., 2018). Further decomposition of H$_2$O$_2$ to H$_2$O and O$_2$ is catalyzed by other antioxidative enzymes within the mitochondria, including glutathione peroxidase (GPx) and peroxiredoxin (PRx)/thioredoxin (TRx) (Mailloux, 2015; Kim et al., 2017; Wang et al., 2018). At low levels, ROS are second messengers for signal transduction and may serve to regulate cellular adaptation against several stressors. However, oxidative stress results when ROS production exceeds homeostatic levels due to an imbalance between ROS production and decomposition.

The kidney is a highly metabolic organ with high levels of oxidation within cellular mitochondria. Renal tissues have a large energy demand, most notably within the proximal tubular cells; this is related to their role in reabsorbing critical nutrients after glomerular filtration. As such, the kidney is particularly vulnerable to damage caused by oxidative stress. Previous reports have shown that mitochondrial oxidative stress may be directly linked to mechanisms underlying the onset and progression of both CKD and AKI (Che et al., 2014; He et al., 2017). Excess mitochondrial ROS may promote mitochondrial dysfunction, ATP depletion, inflammation, and apoptosis in association with kidney disease (Che et al., 2014; He et al., 2017). Among ROS scavenging enzymes in the mitochondrial matrix, Mn-SOD has a primary responsibility for O$_2$$^•−$ scavenging within mitochondria; as such, dysfunction of Mn-SOD results in mitochondrial oxidative stress. Collective experimental evidence has suggested a relationship between Mn-SOD dysfunction and the pathogenesis of kidney disease. In this review, we consider the significance of mitochondrial oxidative stress on the pathogenesis of kidney disease, including CKD and AKI, with a focus on the role of Mn-SOD dysfunction.

**BIOLOGICAL FUNCTION OF MANGANESE SUPEROXIDE DISMUTASE ON REACTIONS AND TRANSFORMATIONS OF SUPEROXIDE ANION**

Human Mn-SOD, encoded by the sod2 gene, is located on chromosome 6q25.3 (Creagan et al., 1973) (Figure 1). The sequence of Mn-SOD is highly conserved, with over 40% homology among proteins from human, yeast, and *Escherichia coli* (Barra et al., 1984). Mn-SOD is a tetrameric enzyme with four identical subunits, each harboring a manganese ion (Mn$^{2+}$/Mn$^{3+}$) as a cofactor. Mn-SOD is located primarily within the mitochondrial matrix (Borgstahl et al., 1992; Karnati et al., 2013). By contrast, Cu/Zn-SOD is localized to the mitochondrial inner membrane space.

**O$_2$$^•−$ production in mitochondria is closely linked to mitochondrial production of adenosine triphosphate (ATP), which takes place via electron transfer linked to nutrient (glucose, amino acids, and fatty acids) metabolism. Electrons are by-products of the tricarboxylic acid (TCA) cycle enzymes and respiratory complexes that promote a univalent reduction of oxygen (O$_2$) to O$_2$$^•−$. Superoxide anion (O$_2$$^•−$) is an important signaling molecule but one that can be toxic at high concentrations. SOD enzymes, including Mn-SOD and Cu/Zn-SOD, catalyze the dismutation of O$_2$$^•−$ to H$_2$O$_2$ in the mitochondrial matrix and the intermembrane space, respectively (Kawamata and Manfredi, 2010; Karnati et al., 2013; Mailloux, 2015). The GPx and PRx/TRx systems convert H$_2$O$_2$ to H$_2$O within the mitochondrial matrix. Alternatively, H$_2$O$_2$ that has diffused into the cytoplasm is metabolized by catalase, GPx, and PRx/TRx. O$_2$$^•−$ can also react with nitric oxide (NO$^•$) to produce peroxynitrite (ONOO$^−$). The decomposition of ONOO$^−$ gives rise to highly oxidizing intermediates, including nitrogen dioxide (NO$_2$$^•$), and hydroxyl radical (OH$^•$); eventually, stable nitrite (NO$_3^−$) is produced (Tharmalingam et al., 2017; Radi, 2018). As such, elevated levels of O$_2$$^•−$ may result in decreased bioavailability of NO and an increased toxic ONOO$^−$ production. Additionally, O$_2$$^•−$ may reduce ferric iron (Fe$^{3+}$) to ferrous iron (Fe$^{2+}$) in iron–sulfur centers in critical proteins, which may lead to enzyme inactivation and concomitant loss of Fe$^{2+}$ from the enzymes, thereby promoting production of H$_2$O$_2$ (Imlay, 2003). H$_2$O$_2$ may then react with Fe$^{2+}$ to produce hydroxyl radicals (OH$^•$) via the Fenton/Haber–Weiss reaction. Moreover, protonation of O$_2$$^•−$ may promote formation of the reactive hydroperoxy radical HO$_2$.

Oxidative stress induced by the imbalance between ROS production and the scavenging capacity of antioxidant protection mechanisms in the mitochondria leads to the inactivation of endogenous antioxidant systems, impairment of the electron transport, uncoupling of oxidative phosphorylation, and altered membrane permeability. As such, internal oxidative stress-mediated damage may be the main cause of mitochondrial dysfunction. Mn-SOD is the primary antioxidative enzyme that is responsible for scavenging O$_2$$^•−$ in the mitochondrial matrix. Therefore, Mn-SOD dysfunction may result in overproduction of highly reactive oxidants, such as ONOO$^−$ and OH, which may result in mitochondrial dysfunction and disease development.

**TRANSCRIPTIONAL REGULATION OF MANGANESE SUPEROXIDE DISMUTASE**

The sod2 gene has three major regulatory regions, namely, a proximal promoter, a 5′ upstream enhancer region, and an intronic enhancer region, which promotes activation or repression of sod2 gene expression (Xu et al., 2002).
FIGURE 1 | Function of manganese superoxide dismutase (Mn-SOD). Superoxide ($O_2^{•−}$) is produced by the electron transport chain (ETC) during nutrient metabolism by the tricarboxylic acid (TCA) cycle. Mn-SOD is localized in the mitochondrial matrix, where it catalyzes the dismutation of $O_2^{•−}$ to $H_2O_2$. By contrast, Cu/Zn-SOD, which is located in the inner membrane space of mitochondria, catalyzes the conversion of $O_2^{•−}$ to hydrogen peroxide ($H_2O_2$). $H_2O_2$ is further metabolized by the glutathione peroxidase (GPx) and the peroxiredoxin (PRx)/thioredoxin (TRx) system in mitochondrial matrix or by catalase (CAT). GPx and PRx/TRx in the cytosol. $O_2^{•−}$ and nitric oxide (NO$^{•−}$) can react to form peroxynitrite (ONOO$^{−}$), giving rise to nitrogen dioxide (NO$^{2•}$) and hydroxyl radical (OH$^{•}$); eventually, stable nitrite (NO$^3−$) is produced. $H_2O_2$ is converted to OH via the Fenton/Haber–Weiss reaction. $O_2^{•−}$ can reduce ferric iron ($Fe^{3+}$) to ferrous iron ($Fe^{2+}$) in iron–sulfur centers of proteins, ultimately resulting in the production of $H_2O_2$. Moreover, the protonation of $O_2^{•−}$ generates the hydroperoxyl radical, $HO_2^{•}$.

Proximal Promotor of the $sod2$ Gene

The basic proximal promoter of the $sod2$ gene has no classical TATA or CAAT box, although it is enriched in CG repeats that contain binding sites for specificity protein 1 (Sp1) and activator protein 2 (AP-2) (Zhu et al., 2001; Xu et al., 2002). Sp1 binding to the promoter activates $sod2$ gene transcription, whereas AP-2 suppresses the transcriptional activity via competition with Sp1 at its binding site or by limiting its bioavailability via AP-2/Sp1 complex formation. As such, Sp1 and AP-2 regulate the basal level of $sod2$ gene transcription via antagonistic mechanisms at the proximal promoter region.

5′ Upstream Enhancer Region of the $sod2$ Gene

The 5′ upstream enhancer region of the $sod2$ gene includes binding sites for activating protein 1 (AP-1) (Borrello and Demple, 1997), cyclic AMP response element-binding protein (CREB) (Kim et al., 1999), nuclear factor, erythroid 2-like 2 (Nrf2) (Taylor et al., 2008), forkhead box O3 (FoxO3a) (Kops et al., 2002), nuclear factor-kappa B (NF-κB) (Warner et al., 1996), and hypoxia-inducible factor 1α (HIF-1α) (Gao et al., 2013). Binding of transcription factors at these sites within the $sod2$ 5′ enhancer leads to an interaction with the basal transcriptional machinery of the proximal promoter, including Sp1. Nrf2 binds to the antioxidant responsive element (ARE) and acts as a master regulator of ARE-responsive antioxidant genes, including $sod2$ at homeostasis and in response to induction (Taylor et al., 2008; Li et al., 2015). FoxO-binding elements were identified upstream of the $sod2$ transcriptional start site; however, only the site at position $−1,249$ mediates FoxO3a-dependent transcription of $sod2$ gene in quiescent cells (Kops et al., 2002). In pathological conditions, activation of Akt (protein kinase B) promotes nuclear exclusion of FoxO3a via phosphorylation, thereby downregulating the transcription of $sod2$ (Kato et al., 2006; Li et al., 2006). FoxO3 is deacetylated...
by sirtuins, including SIRT1, SIRT2, and SIRT3, resulting in enhanced DNA binding and sod2 gene transcription (Jacobs et al., 2008). HIF-1α represses sod2 gene transcription in association with renal clear cell carcinoma (Gao et al., 2013). High levels of mitochondrial O$_2^•$− that result from the repression of sod2 gene expression lead to HIF-1α stabilization. Moreover, peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) also displays antioxidant defense responses via its role in promoting upregulated expression of antioxidative enzymes, including sod2 (Valle et al., 2005; St-Pierre et al., 2006; Lu et al., 2010). PGC-1α also plays an important role in mitochondrial biogenesis and respiration (Wu et al., 1999; Lin et al., 2005). Ding et al. (2017) reported that knockdown of SIRT3 by increasing its acetylation and via downregulated expression of Mn-SOD; this results in elevated levels of ROS and reduced mitochondrial biogenesis and function. Cherry et al. (2014) reported that PGC-1α promotes mitochondrial biogenesis and induces expression of antioxidative enzyme, most notably Nrf2-mediated Mn-SOD expression in the liver of mice of Staphylococcus aureus-induced peritonitis.

Binding sites for p53 were identified in the 5’ upstream region of the sod2 gene (Pani et al., 2000; Drane et al., 2001). p53 exerts its inhibitory action via the prevention of Sp1 binding to the proximal promoter of sod2 gene (Dhar et al., 2006). Additionally, high levels of p53 expression serve to suppress sod2 expression, whereas low levels of p53 expression promote NF-κB binding to the enhancer region of the sod2 gene and increasing sod2 transcription (Dhar et al., 2010). In contrast, Hussain et al. (2004) reported that the promoter of sod2 contains p53 consensus binding sites, which located at −2,009 to −2,032 bp upstream of the transcription start site and induction of p53 leads to increased promoter activity and gene expression.

**Intronic Enhancer Region of the sod2 Gene**

The intronic enhancer contains a primary binding site for NF-κB (Jones et al., 1997; Xu et al., 1999). NF-κB positively regulates transcription via binding to the intronic enhancer region, which is located in the second intron of the sod2 gene by promoting interactions with CCAAT/enhancer-binding protein beta (C/EBP-β; Xu et al., 1999; Jones et al., 1997). NF-κB binding at the intronic enhancer region also enhances transcriptional activity of Sp1 in the proximal promoter of sod2 (Ennen et al., 2011).

**POSTTRANSLATIONAL REGULATION OF MANGANESE SUPEROXIDE DISMUTASE ACTIVITY**

In addition to transcriptional regulation, previous reports indicated that Mn-SOD function is regulated by posttranslational modifications, including nitration, acetylation, phosphorylation, and glutathionylation.

**Nitration**

NO, a ubiquitous intracellular messenger, plays crucial roles in a variety of biological processes (Beckman and Koppenol, 1996). Overproduction of NO and O$_2^•$− leads to the formation of the extremely reactive ONOO−, which can result in lipid peroxidation, DNA damage, and protein nitration. ONOO− can generate covalent modifications of tyrosine (Tyr) residues in proteins, thereby reducing their functionality (Figure 2).

ONOO− leads to Mn-SOD deactivation via nitration of the critical active-site Tyr34 residue (MacMillan-Crow et al., 1998; Yamakura et al., 1998; Yamakura and Kawasaki, 2010) (Figure 2). Mn-SOD protects cells by O$_2^•$− scavenging, thereby preventing the interaction of O$_2^•$− with NO. However, Mn-SOD deactivation leads to the amplification of oxidative stress via accumulation of more O$_2^•$− that promotes not just only ONOO− formation in the mitochondria but also both the onset and progression of several diseases.

**Acetylation**

Nε-lysine acetylation is recognized as a critical posttranslational modification that regulates protein function, most notably that of histones (Narita et al., 2019). Non-histone protein acetylation modulates numerous cellular processes, including gene transcription, DNA damage and repair, cell division, signal transduction, protein folding, autophagy, and metabolism.

Sirtuins (SIRTs), which are NAD-dependent protein deacetylases, play significant roles in the regulation of protein
acetylation (Guarente, 2011). SIRT3, SIRT4, and SIRT5 have been identified in the mitochondria (Guarente, 2011; Kitada et al., 2019). The deacetylase activity of SIRT3 is substantially higher than that of SIRT4 or SIRT5; as such, SIRT3 plays a critical role in mitochondrial biology and pathophysiological processes, including redox status, via its capacity to regulate acetylation of lysine (K) residues in mitochondrial proteins (Guarente, 2011; van de Ven et al., 2017; Kitada et al., 2019). Mn-SOD is among the target proteins of SIRT3. Chen et al. (2011) found that Mn-SOD K68 is an important site for SIRT3 regulation in human cells, whereas Tao et al. (2010) identified K122 and Qiu et al. (2010) identified K53 and K89 in Mn-SOD as the main sites of Sirt3 deacetylation in mouse cells (Figure 2). Overall, we conclude that SIRT3 deacetylates Mn-SOD at several lysine residues. SIRT3-mediated deacetylation results in enhanced Mn-SOD activity within a given nutrient and redox state and under various pathophysiological conditions. This results in decreased mitochondrial oxidative stress and prevents the progression of cellular aging and aging-related disease.

Other Modifications

Mn-SOD can also be phosphorylated, and this process has a direct impact on enzyme function. Candas et al. (2013) reported that the CyclinB1/CDK1-induced phosphorylation of Mn-SOD at Ser106 led to Mn-SOD activation and increased stability, which was associated with improved mitochondrial function and cellular resistance to apoptosis due to radiation. Additionally, cyclin-dependent kinase 4 (CDK4) located in mitochondria directly phosphorylates Mn-SOD at Ser106, resulting in increased Mn-SOD activity and mitochondrial respiration, notably in skin tissues of mice receiving whole-body low-dose ionizing radiation (Jin et al., 2015). The phosphorylation at Ser106 of Mn-SOD enhances its tetrameric conformation, stability, and enzymatic activity. By contrast, Hopper et al. (2006) reported an inverse correlation between phosphorylation and activity of Mn-SOD in mitochondria isolated from pig heart, and Ca$^{2+}$-induced dephosphorylation increased Mn-SOD enzymatic activity. Thus, further studies are necessary to clarify how the phosphorylation or dephosphorylation of Mn-SOD is involved in the regulation of Mn-SOD activity.

Additionally, Zhao et al. (2017) identified Mn-SOD oxidation at histidine (His54 and His55), tyrosine (Tyr58), tryptophan (Trp147, Trp149, Trp205, and Trp210), and asparagine (Asn206 and Asn209) residues in human kidney tissues through mass spectrometry. In renal carcinoma cells, Mn-SOD oxidation at histidine (His54 and His55), tyrosine (Tyr58), and tryptophan (Trp147 and Trp149) residues was enhanced and associated with Mn-SOD deactivation (Zhao et al., 2017). John et al. (2009) also found that oxidation at His54 and His55 was associated with Mn-SOD deactivation in human medulloblastoma cells (John et al., 2009).

S-glutathionylation is the term that describes the addition of glutathione to cysteine residues of proteins; this process prevents irreversible oxidation of protein thiols and regulates a diverse array of cellular processes (Mailloux and Willmore, 2014). Mn-SOD can undergo S-glutathionylation within the mitochondria. Hopper et al. (2006) reported S-glutathionylation of recombinant rat Mn-SOD that was generated in E. coli. Mn-SOD cysteine (Cys) 196 was identified as a target of S-glutathionylation in the rat (Castellano et al., 2009). Patil et al. (2013) demonstrated that diamide, a biochemical that oxidizes glutathione and thus promotes protein glutathionylation, promoted reversible reductions in Mn-SOD activity when added to cultured rat renal tubular cells or when used to perfuse rat kidney in vivo.

**PHYSIOLOGICAL SIGNIFICANCE OF MANGANESE SUPEROXIDE DISMUTASE ON KIDNEY DISEASE IN ANIMAL STUDIES**

**Lessons From Manganese Superoxide Dismutase Gene-Altered Mice**

Studies featuring knockout (KO) of Mn-SOD activity via inactivating mutations or due to the complete elimination of Mn-SOD expression have been performed in mice. These manipulations have resulted in massive oxidative stress and neonatal death associated with cardiomyopathy, neurodegeneration, lipid accumulation in the liver and skeletal muscle, and metabolic acidosis (Li et al., 1995; Holley et al., 2012). There were no obvious alterations in mitochondrial structure in Mn-SOD gene-deleted (−/−) mice; however, this gene deletion had a substantial impact on mitochondrial enzyme activity, including significant reductions in the activity of both succinate dehydrogenase and aconitase when compared with wild-type mice. By contrast, Lebovitz et al. (1996) previously generated a line of Mn-SOD knockout mice (SOD2<sup>mlBCM/mlBCM</sup>), in which the phenotype of mice is different from Mn-SOD knockout mice produced by other groups. Their mice survived longer than other group's mice and exhibited extensively swollen and damaged mitochondria within degenerating neurons and cardiac myocytes. These discrepancies on the phenotype of Mn-SOD knockout mice possibly depend on differences in the molecular constructs used to generate the deletions and in the genetic backgrounds on which the mutations were being bred. Williams et al. (1998) reported that Mn-SOD heterozygotes (±) exhibited a 50% decrease in Mn-SOD activity, which was associated with impaired function and increased oxidative stress in the mitochondria in liver cells. Van Remmen et al. (2003) also reported increased and lifelong oxidative damage to DNA in liver, brain, and heart tissues of the Mn-SOD± mice; oxidative damage to DNA was associated with an increased incidence of cancer in these mice.

The physiological and pathological roles of Mn-SOD concerning renal function have been investigated using the heterozygous Mn-SOD± mice and with renal-specific Mn-SOD KO mice. Rodriguez-Iturbe et al. (2007) demonstrated oxidative stress and renal interstitial inflammation in a cohort of Mn-SOD± mice. These alterations were found to be compatible with accelerated renal senescence and the development of salt-sensitive hypertension. Additionally, Parajuli et al. (2011) created kidney-specific Mn-SOD KO mice from two different transgenic mouse lines. Specifically, “floxed” Mn-SOD mice (exon 3 of Mn-SOD allele flanked with LoxP sites in introns 2 and 3) were crossed with transgenic Ksp1.3/Cre (kidney Cre) mice.
The Ksp1.3/Cre transgenic mice expressed Cre recombinase specifically in distal tubules, collecting ducts, loops of Henle, ureteric buds, and the developing genitourinary tract of the kidney. As such, the impact of the Mn-SOD KO is limited to these specific parts of the kidney. Kidney-specific Mn-SOD KO mice exhibited normal renal function; however, the localized Mn-SOD KO resulted in modest renal damage, including tubular dilation, epithelial cell enlargement, the formation of casts within the tubular lumen, and the accumulation of nitrotyrosine-modified protein. These data indicate that Mn-SOD plays a crucial role in maintaining redox homeostasis in kidney mitochondria.

**Kidney Disease Animal Model Studies**

Mitochondrial oxidative stress associated with Mn-SOD dysfunction in the kidney is involved in the pathogenesis of several kidney diseases, including AKI and CKD, as well as in the AKI to CKD transition. Mn-SOD dysfunction has been associated with glomerular and tubulointerstitial fibrosis, inflammation, excess apoptosis of renal cells, and tubular cell damage, as one of the sources of ROS in the mitochondria (Figure 3). We focused on the change of Mn-SOD in the kidney, such as posttranslational modification, activity, and expression levels, in animal models of kidney disease, and showed the summary in Table 1.

**Ischemia/Reperfusion-Induced Acute Kidney Injury**

Increased oxidative stress is a well-known factor that contributes to renal ischemia/reperfusion (I/R) injury (Noiri et al., 2001). Mitochondria are remarkably sensitive to I/R injury, as I/R rapidly promotes the generation of O$_2$-$\bullet$ and other ROS, including ONOO$^-$, within the injured mitochondria (Walker et al., 2000).

In the kidney of a rodent model of I/R AKI, Cruthirds et al. (2003) reported an acute increase in oxidative stress associated with increased levels of mitochondrial protein nitration, including Mn-SOD and cytochrome c, which resulted in Mn-SOD deactivation and mitochondrial dysfunction. Additionally, renal SIRT3 activity was reduced in response to I/R-induced AKI compared with activity observed among those in the control/sham-operated group. This was also accompanied by increased acetylation of both Mn-SOD and p53 (Ouyang et al., 2019). Taken together, these results suggest that inactivation of Mn-SOD induced by posttranslational modifications, such as nitration and acetylation, results in accelerated renal mitochondrial oxidative stress and contributes to the progression of I/R-induced AKI.

Le Clef et al. (2016) established a unilateral renal I/R model to study the associated mechanisms and therapies directed toward inhibiting the AKI to CKD transition in mice. Zhang et al. (2018) demonstrated that the mitochondrial complex-1 inhibitor, rotenone, slows the progression of AKI to CKD. By the mitochondrial complex-1 inhibitor, the expression of Mn-SOD and ATP synthase subunit $\beta$, mitochondrial DNA copy number, were restored, and inflammation and fibrosis were suppressed, in this model. These data suggest that mitochondrial O$_2$-$\bullet$ may play a crucial role in promoting the pathogenesis associated with the transition from AKI to CKD.

**FIGURE 3** Mitochondrial oxidative, manganese superoxide dismutase (Mn-SOD) dysfunction, and kidney disease. Mitochondrial oxidative stress associated with Mn-SOD dysfunction in the kidney is one of the key factors underlying the pathogenesis of kidney disease, including acute kidney injury (AKI), chronic kidney disease (CKD), as well as the AKI to CKD transition through glomerular and tubulointerstitial fibrosis, inflammation, excessive apoptosis of renal cells, and tubular cell damage. Several mitochondria-targeted drugs may improve the kidney disease through the improvement of mitochondrial oxidative stress. I/R, ischemia/reperfusion; DKD, diabetic kidney disease; HT, hypertension; UUO, unilateral ureteral obstruction.
Sepsis-Associated Acute Kidney Injury

Oxidative stress plays a crucial role in the development of mitochondrial dysfunction in response to septic AKI (Schrier and Wang, 2004). Patil et al. (2014) reported a decrease in renal Mn-SOD activity in association with the experiment in sepsis mice, which led to mitochondrial oxidative stress. Treatment with Mito-TEMPO, a mitochondrial-targeted mimic of SOD, resulted in improvements in sepsis-induced AKI, which were directly associated with increased activation of Mn-SOD and decreased mitochondrial oxidative stress. Additionally, Chen G. D. et al., 2018 demonstrated that renal Mn-SOD expression and activity were reduced in sepsis-induced AKI and that insulin therapy reversed mitochondrial dysfunction via the suppression of the oxidative stress associated with upregulation of Mn-SOD. Furthermore, Xu (2016) found that SIRT1/SIRT3 activity was reduced in the renal tubular epithelial cells of rats with sepsis-associated AKI. This finding was accompanied by increasing levels of acetylated Mn-SOD, swollen mitochondria, and elevated levels of cellular apoptosis. Interestingly, activation of SIRT1 via treatment with resveratrol...
Diabetic Kidney Disease

Diabetic kidney disease (DKD) is among the main causes of ESRD and an independent risk factor for CVD. Other Acute Kidney Injury Models

Glycerol-induced AKI results in increased expression of phosphorylated p53 in renal tissues in association with elevated levels of tubular cell apoptosis and oxidative stress due to decreased expression of antioxidative enzymes, including Mn-SOD (Homsii et al., 2011). Treatment with the p53 inhibitor, pifithrin-α, reversed features of glycerol-induced renal injury, including tubular cell apoptosis and oxidative stress via its capacity to restore Mn-SOD expression in the kidney (Homsii et al., 2011).

Oxidative stress and mitochondrial dysfunction related to ATP depletion have been observed in response to cisplatin-induced cellular injury in the kidney (Arany and Szafirstein, 2003). Rattanovich et al. (2013) reported that cisplatin treatment results in diminished expression of renal Mn-SOD via the enhanced expression of phospho-p66ShcA and phospho-Foxo3A in studies featuring heterozygous p66ShcA (+/−) mice. Specifically, increased expression of phospho-p66ShcA and phospho-Foxo3A was detected in the renal tissue of wild-type mice treated with cisplatin in association with reduced expression of both Mn-SOD and catalase. By contrast, renal tissue from cisplatin-treated p66ShcA+/− mice revealed attenuated phosphorylation of p66ShcA and Foxo3a, together with a restored expression of Mn-SOD and catalase.

In the folic acid (FA)-induced AKI model, mitochondrial DNA copy number and expression of mitochondrial cytochrome c oxidase subunit 1, mitochondrial NADH dehydrogenase subunit 1, and Mn-SOD in the kidney were all reduced. These findings implicate mitochondrial dysfunction and oxidative stress in the pathogenesis of FA-induced AKI (Zhang et al., 2019). However, pretreatment with rotenone aggravated the renal injury, mitochondrial damage, and oxidative stress in this mouse model of AKI.

Chronic Renal Allograft Rejection

Chronic allograft rejection is currently the most important cause of renal transplant failure (Shrestha and Haylor, 2016). At the tissue level, increased oxidative stress observed in response to I/R may contribute to chronic allograft rejection and associated nephropathy. MacMillan-Crow et al. (1996, 2001) previously reported that endogenous tyrosine nitration and inactivation of Mn-SOD were observed in both human recipients and rat models of chronic renal allograft rejection. These data suggest that deactivation of Mn-SOD by ONOO− results in a progressive increase in the production of ONOO−, leading to irreversible oxidative injury to mitochondria in the renal allograft.

Diabetic Kidney Disease

Diabetic kidney disease (DKD) is among the main causes of ESRD and an independent risk factor for CVD. Partially restored SIRT3 activity, which led to improved mitochondrial function and reduced levels of apoptosis. Taken together, these data indicate that Mn-SOD dysfunction and associated mitochondrial oxidative stress are both closely linked to mechanisms promoting disease pathogenesis in sepsis-related AKI.

Hypertension-Related Kidney Injury

Oxidative stress in blood vessels and the kidney due to chronic hypertension may result from the dysregulated responses of
several vasoconstrictor mechanisms, including those associated with angiotensin II stimulation or with dysfunction of nitric oxide synthase (eNOS). Angiotensin II-induced hypertension promotes an increase in $O_2^{•−}$ generation via the activation of NADPH oxidase (Wang et al., 2001; Onozato et al., 2002). The antioxidant response is impaired in hypertensive animals, which results in oxidative stress followed by the development of end-organ damage, including ESRD. Guo et al. (2003) demonstrated that angiotensin II-induced hypertension in rats was accompanied by increased tyrosine nitration and thus deactivation of Mn-SOD that serves to augment oxidative stress in the kidney. Activation of NADPH oxidase also induces the production of $O_2^{•−}$, and ONOO$^−$ also may induce eNOS uncoupling, leading to overproduction of $O_2^{•−}$ as opposed to NO.

Protein nitration was increased in the renal cortex of SHRs treated with the NOS inhibitor, L-NAME (Majzunova et al., 2019). Renal expression of Mn-SOD was increased in SHR in response to treatment with L-NAME, although total SOD activity remained unchanged (Majzunova et al., 2019). These data suggest that the impaired antioxidant response combined with a deficiency in NO may promote oxidative damage of proteins in the kidney via the production of ONOO$^−$ in SHRs. By contrast, SHRs that fed a high-fat diet (HFD) developed renal lipotoxicity, insulin resistance, and hypertension in association with a decrease in PPAR$\alpha$ expression. This leads to Akt activation, increased FoxO3a phosphorylation, suppression of the PGC-1$α$-ERR-$1α$ pathway, reduced expression of Mn-SOD, and increased oxidative stresses (Chung et al., 2012).

**Aging-Related Kidney Dysfunction**

Aging-related changes lead to the functional decline of several organs, including the kidney. Oxidative stress, particularly mitochondrial oxidative stress, has been recognized as one of the contributors to the aging process (Vlassara et al., 2009; Kume et al., 2010). Reduction or dysfunction of Mn-SOD-mediated mitochondrial oxidative stress may be involved in the pathogenesis associated with the aging kidney.

Lim et al. (2012) reported increased oxidative stress in the kidneys of aged (24 months old) mice compared with that observed among younger mice. This finding was associated with a reduction in Cu/Zn-SOD and Mn-SOD expression in the kidney, which may be mediated by decreases in SIRT1, PGC-1$α$, estrogen-related receptor (ERR)-$1α$, PPAR$\alpha$, and Klotho. Klotho has been identified as an antiaging gene that is primarily expressed in the kidney, parathyroid, and choroid plexus (Kuro-o et al., 1997); decreased Klotho expression has been correlated with kidney disease. Klotho exerts resistance against oxidative stress, possibly via the activation of FoxO transcription factors, which lead to increased expression of antioxidative enzymes, including Mn-SOD (Yamamoto et al., 2005). Klotho$^{−/−}$ mice exhibit enhanced nitrotyrosine levels and reduced levels of antioxidative enzymes, including Mn-SOD in the kidney (Kimura et al., 2018). Additionally, Hou et al. (2016) demonstrated that the production of endogenous hydrogen sulfide (H$_2$S) in the aging kidney is insufficient. Exogenous H$_2$S can reduce renal oxidative stress in aging mice via a mechanism that involves enhanced nuclear translocation of Nrf2 and increased expression of antioxidative enzymes, including Mn-SOD (Hou et al., 2016). Moreover, the endogenous advanced glycated end products (AGEs)/receptor for AGEs (RAGE) axis mediates factors associated with the aging process in many tissues and organs, including the kidney. Teissier et al. (2019) showed that older (20 months old) WT mice exhibited renal inflammation and oxidative stress with reduced expression of Mn-SOD compared with 3-month-old counterparts. By contrast, 20-month-old RAGE$^{−/−}$ mice were characterized by lower inflammation and elevated expression levels of Mn-SOD and SIRT1 in the kidney compared with their 20-month-old WT counterparts (Teissier et al., 2019). By contrast, Gomes et al. (2009) detected increased levels of NADPH oxidase subunits and H$_2$O$_2$ in aged Wistar-Kyoto rats (52 weeks old) compared with those in young rats, although aged rats show no renal functional impairment or marked elevation in blood pressure. The aged rats did exhibit increased expression of antioxidative enzymes, including Mn-SOD, extracellular Cu/Zn-SOD, and catalase (Gomes et al., 2009), and these findings reveal that increases in antioxidant defenses may be useful for counteracting the damaging impact of oxidative stress.

**Other Chronic Kidney Disease Animal Models**

Albumin overload is a well-known model of renal tubulointerstitial injury caused by inflammation and fibrosis (Eddy, 1989). In the kidney of albumin-overload mice, Mn-SOD expression is reduced, thus promoting mitochondrial oxidative stress and inflammation. This condition can be improved by treatment with an Mn-SOD mimic [Mn (III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP)] (Zhuang et al., 2015; Jia et al., 2016).

Unilateral ureteral obstruction (UOO) in a rodent model generates progressive renal fibrosis (Chevalier et al., 2009). Oxidative stress and inflammation are closely associated with the pathogenesis of UOO-induced renal fibrosis (Chevalier et al., 2009). In the kidney of UOO mice, the expression of antioxidative enzymes, including Mn-SOD, is reduced, resulting in mitochondrial oxidative stress, inflammation, and tubular epithelial–mesenchymal transition (EMT; Li et al., 2017; Liu et al., 2017). This condition can be improved by treatment with MnTBAP (Li et al., 2017; Liu et al., 2017).

**PHYSIOLOGICAL SIGNIFICANCE OF MANGANESE SUPEROXIDE DISMUTASE ON KIDNEY DISEASE IN HUMAN STUDIES**

**Manganese Superoxide Dismutase Gene Polymorphisms on Diabetic Kidney Disease**

A16Val (rs4880C/T) is a functional Mn-SOD SNP polymorphism in exon 2 of sod2 gene. The substitution of
C to T (GCT to GTT), resulting in the conversion from alanine (A) to valine (V), induces a conformational change in the mitochondrial targeting sequence. This results in less efficient transport of Mn-SOD into the mitochondrial matrix and decreases antioxidant activity within the mitochondria (Shimoda-Matsubayashi et al., 1996; Sutton et al., 2003). The relationship of this Mn-SOD gene polymorphism with DKD has been studied widely.

Previous reports revealed an association between the Mn-SOD gene polymorphism and the risk for developing DKD. Möllsten et al. (2007) reported that VV genotype was associated with an increased risk of diabetic nephropathy among Finnish and Swedish patients with type 1 diabetes. Nomiyama et al. (2003) identified the VV genotype with significantly higher frequency in the diabetic patients with nephropathy compared with the AA or VA genotype; however, this was unrelated to the etiology of type 2 diabetes in Japanese patients. By contrast, Houldsworth et al. (2015) demonstrated that the CC (alanine/alanine) genotype in type 1 diabetic patients might protect against diabetic nephropathy. According to another study on Korean type 2 diabetic patients, the alanine-encoding allele was detected at significantly lower frequency among patients with nephropathy who have micro- or macroalbuminuria compared with those patients without nephropathy (Lee et al., 2006). Liu et al. (2009) showed that the AA and VA genotypes were independent factors that protected against the development of nephropathy in Chinese type 2 diabetic patients. Ascencio-Montiel et al. (2013) demonstrated that in type 2 diabetes patients from Mexico, the frequency of the TT (valine/valine) genotype was 6.7% higher in patients with macroalbuminuria than in those in the normoalbuminuria group; the CC (alanine/alanine) genotype was associated with a lower risk of macroalbuminuria than the TT (valine/valine) genotype (Tian et al., 2011). Moreover, in a meta-analysis that included five studies focusing on type 2 diabetic patients, the alanine-encoding allele was associated with a reduced risk of macroalbuminuria (CR 0.65, 95% CI 0.52–0.80) compared with the valine-encoding allele (Tian et al., 2011). Likewise, a meta-analysis that included 17 published articles with both type 1 and 2 diabetic patients revealed a significant association of the alanine-encoding allele with a reduced risk of diabetic microvascular complications and nephropathy in the dominant model (OR 0.788, 95% CI 0.680–0.914 and OR 0.801, 95% CI 0.664–0.967, respectively) (Ascencio-Montiel et al., 2013).

**Membranous Nephropathy**

Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. Glomerular damage is induced by subepithelial immune deposits that consist mainly of IgG4 and complement components C5b-9. Several podocyte proteins, including aldose reductase (AR) and Mn-SOD, have been identified as renal antigens associated with the pathogenesis of MN (Prunotto et al., 2010). Confocal and immunoelectron microscopy (IEM) displayed co-localization of anti-AR and anti-Mn-SOD IgG4 and C5b-9 in electron-immune deposits in podocytes. Additionally, Murtas et al. (2012) demonstrated that the levels of serum IgG4 directed against AR and Mn-SOD in patients with MN are higher in MN than those in any of the other proteinuria-associated glomerulonephritides, including focal glomerulonephropathy and IgA nephritis.

### MITOCHONDRIA-TARGETED THERAPIES FOR SCAVENGING O$_{2}^{-}$

Mitochondria are both sources and targets of ROS. The dysfunction of mitochondria due to oxidative stress may be the causal factor for kidney disease. As such, it will be necessary to develop pharmacological methods aimed at reducing oxidative damage to mitochondria and their components, including Mn-SOD. Several molecules that accumulate within the mitochondria and can scavenge ROS have been developed to address this issue. The beneficial effect of mitochondria-targeted drugs for kidney injury has been shown in several animal models (Table 2). However, those drugs are not delivered to only the kidney; therefore, the risk of adverse effects in systemic administration remains. To address this issue, it is necessary to develop the drugs that specifically deliver to the kidney.

**MitoQ**

MitoQ is a derivative of ubiquinone conjugated to triphenylphosphonium (TTP), a lipophilic cation that enables this molecule to enter and accumulate within the mitochondria via an electrochemical gradient (Smith et al., 2003; Smith and Murphy, 2010). In the mitochondrial matrix, MitoQ is reduced to the active antioxidant form, ubiquinol, by the respiratory chain, which serves to protect the mitochondria and their components from oxidative damage (Smith et al., 2003; Smith and Murphy, 2010). Additionally, MitoQ is cleared rapidly from the plasma after intravenous administration and accumulates within the kidney (Porteous et al., 2010; Smith and Murphy, 2010). Previous animal studies have revealed the beneficial effects of MitoQ in association with various kidney disorders, including I/R-induced AKI (Dare et al., 2015; Kaczik et al., 2016), sepsis-induced AKI (Lowes et al., 2008), cisplatin-induced kidney injury (Mukhopadhyay et al., 2012), DKD (Chacko et al., 2010; Xiao et al., 2017; Han et al., 2018), and polycystic kidney disease (Ishimoto et al., 2017).

**SkQ1 and SkQR1**

SkQ1 is a compound of plastoquinonyl-decyltriphenylphosphonium in which ubiquinone was replaced by plastoquinone (Antonenko et al., 2008). SkQR1 is also a mitochondria-targeted compound and a conjugate of a positively charged rhodamine molecule with plastoquinone (Antonenko et al., 2008). SkQs, including SkQ1 and SkQR1, penetrate planar phospholipid membranes, and as such, they can accumulate in mitochondria (Antonenko et al., 2008). Administration of SkQ1 to mitochondrial DNA mutator mice resulted in diminished renal oxidative stress and mitochondrial dysfunction (Shabalina et al., 2017). In experimental rats with I/R injury, SkQR1 treatment...
TABLE 2 | Mitochondria-targeted drugs and animal models of kidney disease.

| Mitochondria-targeted drugs | Antioxidative moiety | Animal models of kidney disease showing the benefit of mitochondria-targeted drugs | References |
|-----------------------------|----------------------|---------------------------------------------------------------------------------|------------|
| MitoQ                        | Ubiquinone           | I/R-induced AKI mice                                                            | Dare et al., 2015 |
|                             |                      | Sepsi-associated AKI rats                                                        | Lowes et al., 2008 |
|                             |                      | Cisplatin-induced AKI mice                                                       | Mukhopadhyay et al., 2012 |
|                             |                      | Lm21(+/−) (Akita/J) mice                                                         | Chacko et al., 2010 |
|                             |                      | db/db mice                                                                       | Xiao et al., 2017; Han et al., 2018 |
|                             |                      | ADPKD model mice (Ksp-Cre PKD1<sup>fox/fox</sup> and rats (Han:SPRD Cy<sup>+/−</sup>) | Ishimoto et al., 2017 |
| SkQ1                        | Plastoquinone        | mtDNA mutator mice                                                               | Shabalina et al., 2017 |
| SkQR1                       |                      | I/R-induced AKI rats                                                              | Plotnikov et al., 2011 |
| SS-31                       | Tyr or Dmt (2′,6′-dimethyltyrosine) residues | Gentamicin-induced AKI rats                                                      | Jankauskas et al., 2012 |
| MnTMPyP                     | Manganese metalloporphyrin | PTRA-induced I/R pig                                                            | Szeto et al., 2011 |
| MnTnHex-2-PyP<sup>5+</sup>  |                      | I/R injury of rats                                                                | Liang et al., 2009 |
| MnTBAP                      |                      | Albumin-overload model mice                                                       | Dorai et al., 2011 |
| Mito-CP                     | Nitroxide CP         | UUO model mice                                                                   | Zhuang et al., 2015; Jia et al., 2016 |
|                             |                      | Cisplatin-induced AKI mice                                                       | Liu et al., 2017 |

MnTMPyP, MnP manganese (III) tetras (1-methyl-4-pyridyl) porphyrin; MnTnHex-2-PyP<sup>5+</sup>, Mn (III) meso-tetras (N-n-hexylpyridinium-2-yl) porphyrin; MnTBAP, Mn (III) tetras (4-benzoic acid) porphyrin chloride; CP, carboxy-proxyl; I/R, ischemic/reperfusion; AKI, acute kidney disease; ADPKD, autosomal dominant polycystic kidney disease; PTRA, percutaneous transluminal renal angioplasty; UUO, unilateral ureteral obstruction.

normalized the ROS levels in kidney mitochondria, decreased blood urea nitrogen (BUN) and creatinine levels, and reduced disease-associated mortality, compared with what was observed among the rats without treatment (Plotnikov et al., 2011). Additionally, SkQR1 was also effective for the treatment of gentamicin-induced AKI (Jankauskas et al., 2012).

**SS-31**

The Szeto–Schiller (SS)-31 peptide, also known as Bendavia, may optimize the mitochondrial phospholipid cardiolipin microdomains. This may lead to reduced electron leak from the inner membrane (Brown et al., 2013). In an experimental model of I/R injury in the kidney, treatment with SS-31 attenuated renal oxidative stress prevented tubular cell apoptosis and necrosis, and reduced inflammation (Szeto et al., 2011). Rapid ATP recovery in mitochondria secondary to administration of SS-31 led to the protection of microvascular endothelial cells, reduced microvascular congestion, and, thus, better reflow to the medulla. In an experimental pig model featuring percutaneous transluminal renal angioplasty, administration of SS-31 resulted in decreased microvascular rarefaction, apoptosis, oxidative stress, tubular injury, and fibrosis, which were all associated with preserved mitochondrial biogenesis in the kidney after reperfusion (Eirin et al., 2012).

**Manganese Superoxide Dismutase Mimics**

Mn-SOD mimics are stoichiometric scavengers of O<sub>2</sub>H· and accumulate in mitochondria depending on their positive charge and lipophilicity (Miriyala et al., 2012). Among the cationic metalloporphyrins, the Mn porphyrins (MnP) are the most potent Mn-SOD mimics; these molecules have been designed and optimized for accumulation in the mitochondria where they mimic the action of the Mn-SOD catalytic site (Miriyala et al., 2012). The MnP manganese (III) tetras (1-methyl-4-pyridyl) porphyrin (MnTMPyP) functions as a peroxynitrite scavenger. Administration of MnTMPyP resulted in diminished lipid peroxidation and reduced nitrotyrosine content in the proximal tubular area in association with reductions in caspase-3 activation and tubular epithelial cell damage after I/R injury in rats (Liang et al., 2009). Similarly, administration of Mn (III) meso-tetras (N-n-hexylpyridinium-2-yl) porphyrin (MnTnHex-2-PyP<sup>5+</sup>) or Mn (III) tetras (4-benzoic acid) porphyrin chloride (MnTBAP) also resulted in protection against the deleterious effects associated with I/R-induced AKI (Dorai et al., 2011) as well as in the albumin-overload kidney injury (Zhuang et al., 2015; Jia et al., 2016) and the UUO model (Liu et al., 2017). Moreover, mitochondria-targeted carboxyproxyl (Mito-CP) is a five-membered nitroxide CP conjugated to the TTP cation. Administration of Mito-CP resulted in improvements in parameters associated with cisplatin-induced AKI, including kidney dysfunction, renal inflammation, and tubular cell apoptosis, which were equivalent to those of MitoQ (Mukhopadhyay et al., 2012).

**CONCLUSION AND PERSPECTIVES**

Mitochondrial oxidative stress is induced by an imbalance between ROS production and scavenging; the scavenging
function may be impaired or destroyed due to dysfunction of antioxidative defense in mitochondria. Mitochondrial oxidative stress contributes to the pathogenesis of kidney disease, including AKI, CKD, and the AKI to CKD transition, and mitochondria-targeted drugs may suppress the onset or progression of kidney disease (Figure 3). Mn-SOD-associated dysfunction is one of the main factors underlying defective antioxidative defense in mitochondria. Mn-SOD dysfunction results in a net increase in ROS and generates a vicious cycle in which mitochondrial oxidative stress is amplified, as Mn-SOD then becomes a target of dysfunctional oxidative modification. An agent with the capacity to scavenge excess ROS in mitochondria would lead to a break in this vicious cycle, serving to preserve Mn-SOD and mitochondrial function and consequently suppress kidney disease. Although Mn-SOD may become dysfunctional in kidney disease, it remains unclear whether mitochondrial oxidative stress due to only Mn-SOD dysfunction is the primary contributor to the pathogenesis of kidney disease. Redox state in mitochondria is regulated by not only Mn-SOD but also other antioxidative enzymes, including Cu/Zn-SOD, GPx, and the PRx/TRx system. However, as Mn-SOD catalyzes the first step in ROS scavenging in mitochondria, treatments targeted at supporting Mn-SOD integrity and function may lead to effective treatments to prevent the onset and progression of kidney disease.

AUTHOR CONTRIBUTIONS

MK designed, wrote, and edited the manuscript. JX, YO, IM, and DK contributed to the discussion. MK was the guarantor of this work. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported in part by the Japan–China Sasakawa Medical Fellowship to JX.
dismutase gene expression. J. Biol. Chem. 281, 21698–21709. doi: 10.1074/jbc.m601083200
Dhar, S. K., Xu, Y., and St. Clair, D. K. (2010). Nuclear factor kappaB- and specificity protein 1-dependent p53-mediated bi-directional regulation of the human manganese superoxide dismutase gene. J. Biol. Chem. 285, 9835–9846. doi: 10.1074/jbc.M109067115
Ding, Y., Yang, H., Wang, Y., Chen, J., Ji, Z., and Sun, H. (2017). Sirtuin 3 is required for osteogenic differentiation through maintenance of PGC-1α to SOD2-mediated regulation of mitochondrial function. Int. J. Biol. Chem. 13, 254–264. doi: 10.7150/ijbci.17053
Dorai, T., Fishman, A. I., Ding, C., Batinic-Haberle, I., Goldfarb, D. S., and Grasso, M. (2011). Amelioration of renal ischemia-reperfusion injury with a novel protective cocktail. J. Urol. 186, 2448–2454. doi: 10.1016/j.juro.2011.08.010
Drane, P., Bravard, A., Bouvard, V., and May, E. (2001). Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis. Oncogene 20, 430–439. doi: 10.1038/sj.onc.1204101
Dugan, L. L., You, Y. H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A. E., et al. (2013). AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J. Clin. Invest. 123, 4888–4899. doi: 10.1172/jci66218
Eckardt, K. U., Coresh, J., Devuyst, O., Johnson, R. J., and Köttgen, A. (2013). Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158–169. doi: 10.1016/s0140-6736(13)60439-0
Eddy, A. A. (1989). Intestinal neoplasia induced by protein-overloaded proteinuria. Am. J. Pathol. 135, 719–733.
Eirin, A., Li, Z., Zhang, X., Krier, J. D., Woollard, J. R., Zhu, X. Y., et al. (2012). A novel mechanism related to diabetic kidney disease. J. Biol. Chem. 287, 158–169. doi: 10.1074/jbc.M111.303759
Ennen, M., Minig, V., Grandemange, S., Touche, N., Merlin, J. L., Besancenot, E., et al. (2017). Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell. Biol. 7:e00337-17. doi: 10.1128/MCB.00337-17
Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382, 158–169. doi: 10.1016/s0140-6736(13)60439-0
Eddy, A. A. (1989). Intestinal neoplasia induced by protein-overloaded proteinuria. Am. J. Pathol. 135, 719–733.
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., and Hemingway, Y. (2012). Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell. Biol. 7:e00337-17. doi: 10.1128/MCB.00337-17
Guo, W., Adachi, T., Matsui, R., Xu, S., Jiang, B., Zou, M. H., et al. (2003). Mammalian Sirtuin 3 is required for osteogenic differentiation through maintenance of PGC-1α to SOD2-mediated regulation of mitochondrial function. Int. J. Biol. Chem. 13, 254–264. doi: 10.7150/ijbci.17053
Hopper, R. K., Carroll, S., Aponte, A. M., Johnson, D. T., French, S., Shen, R. F., et al. (2006). Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. Biochemistry 45, 2524–2536. doi: 10.1021/bi052475e
Hou, C. L., Wang, M. J., Sun, C., Huang, Y., Jin, S., Mu, X. P., et al. (2016). Protective effects of hydrogen sulfide in the ageing kidney. Oxid. Med. Cell Longev. 2016:7570489.
Han, Y., Xu, X., and St. Clair, D. K. (2012). Manganese superoxide dismutase: beyond life and death. Amino Acids 42, 139–158. doi: 10.1007/s00726-010-0600-9
Homsí, E., Mota da Silva, S. J., Machado de Brito, S., Bouçaia Inácio Peixoto, E., Buitier Lopes de Faria, J., and Janino, P. (2011). p53-Mediated oxidative stress and tubular injury in rats with glyceral-induced acute kidney injury. Am. J. Nephrol. 33, 49–59. doi: 10.1159/000322836
Hou, Y., Shi, Y., Han, B., Liu, X., Qiao, X., Qi, Y., et al. (2018). The antioxidative peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy. Nephrol. Dial. Transplant. 33, 1908–1918. doi: 10.1093/ndt/gfy021
Houldsworth, A., Hodgkinson, A., Shaw, S., Millward, A., and Demaine, A. G. (2015). Polymorphic differences in the SOD2 gene may affect the pathogenesis of nephropathy in patients with diabetes and diabetic complications. Gene 569, 41–45. doi: 10.1016/j.gene.2015.04.006
Hussain, S. P., Amstad, P., He, P., Robles, A., Lupold, S., Kaneko, I., et al. (2004). P53-induced up-regulation of MnSOD and GPX but not catalase increases oxidative stress and apoptosis. Cancer Res. 64, 2350–2356. doi: 10.1158/0008-5472.can-2287-2
Imlay, J. A. (2003). Pathways of oxidative damage. Annu. Rev. Microbiol. 57, 393–418. doi: 10.1146/annurev.micro.57.030502.090938
Ishimoto, Y., Imagi, R., Yoshidara, D., Kugita, M., Nagao, S., Shimizu, A., et al. (2012). Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell. Biol. 7:e00337-17. doi: 10.1128/MCB.00337-17
Jacinth, M. C., Nanjung, Y., Hu, C., Zhang, X., Ding, G., Zhang, Y., et al. (2016). Albuminuria enhances NHE3 and NCC via stimulation of mitochondrial oxidative stress/angiotensin II axis. Oncotarget 7, 47134–47144. doi: 10.18632/oncotarget.9972
Jin, C., Qin, L., Shi, Y., Candás, D., Fan, M., Lu, C. L., et al. (2015). CDK4-mediated MnSOD activation and mitochondrial homeostasis in radiodaptive protection. Free Radic. Biol. Med. 81, 77–87. doi: 10.1016/j.freeradbiomed.2014.12.026
John, J. P., Pollak, A., and Lubec, G. (2009). Complete sequencing and oxidative modification of manganese superoxide dismutase in medulloblastoma cells. Biochem. Biophys. Res. Commun. 381, 1970–1975. doi: 10.1016/j.bbrc.2009.02.086
Kawamata, H., and Manfredi, G. (2010). Import, maturation, and function of SOD1 and SOD2. Histochem. Cell Biol. 133, 2245–2250. doi: 10.1007/s00418-009-0559-x
Karnati, S., Luers, G., Pfreimer, S., and Baumgart-Vogt, E. (2013). Mammalian MnSOD is exclusively located in mitochondria and not present in peroxisomes. Histochem. Cell Biol. 140, 105–117. doi: 10.1007/s00418-013-1099-4
Kato, M., Yuan, H., Xu, Z. G., Lanting, L., Li, S. L., Wang, M., et al. (2006). Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J. Am. Soc. Nephrol. 17, 3325–3335. doi: 10.1111/j.1600-0670.2006.00754.x
Kim, H. P., Roe, J. H., Chock, P. B., and Yim, M. B. (1999). Transcriptional activation of the human manganese superoxide dismutase gene mediated by tetradecanoylphorbol acetate. J. Biol. Chem. 274, 37455–37460. doi: 10.1074/jbc.274.52.37455
Kim, Y. S., Gupta Vallur, P., Phaeton, R., Mythreye, K., and Hempel, N. (2017). Insights into the dichotomous regulation of SOD2 in cancer. Antioxidants e686. doi: 10.3390/antioxid6040086
Kimura, T., Shizui, K., Akimoto, T., Shinzato, T., Shimizu, T., Kurosawa, A., et al. (2018). The impact of preserved Klotho gene expression on antioxidative stress activity in healthy kidney. Am. J. Physiol. Renal Physiol. 315, F345–F352.
Kitada, M., Kume, S., Imaizumi, N., and Koya, D. (2011). Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes Metab. Res. Rev. 60, 634–643. doi: 10.2337/db10-0386
Kitada, M., Ogura, Y., Monno, I., and Koya, D. (2019). Sirtuins and Type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Front. Endocrinol. 10. doi: 10.3389/fendo.2019.00187
Kops, G. J., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W., Coffer, P. I., et al. (2002). Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316–321. doi: 10.1038/nature01036
Kume, S., Uru, T., Horiike, K., Chin-Kanasaki, M., Ishiki, K., Araki, S., et al. (2010). Calorie restriction enhances cell adaptation to hypoxia through Sirtuin-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest. 120, 1043–1055. doi: 10.1172/jci41376
Kuro-o, M., Matsushita, Y., Aizaki, H., Sugahara, H., Suga, T., Utsugi, T., et al. (2001). A critical role for the transcription factor Foxo1 in the regulation of renal mitochondria dysfunction in diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 98, 11853–11858. doi: 10.1073/pnas.93.21.11853
MacMillan-Crow, L. A., Crow, J. P., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., et al. (2019). The impact of preserved Klotho gene expression on antioxidative stress and renal outcomes in diabetes. J. Am. Soc. Nephrol. 30, 1813–1821. doi: 10.1021/bi911802w
Lowes, D. A., Thottakam, B. M., Webster, N. R., Murphy, M. P., and Galley, H. F. (2008). The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic. Biol. Med. 45, 1559–1565. doi: 10.1016/j.freeradbiomed.2008.09.003
Lu, Q., Zhai, Y., Cheng, Q., Liu, Y., Gao, X., Zhang, T., et al. (2013). The Akt-FOXO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy. Exp. Physiol. 98, 934–945. doi: 10.1113/exphysiol.2012.068361
Lu, Z., Xu, X., Hu, X., Fasset, J., Zhu, G., Tao, Y., et al. (2010). PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid. Redox. Signal. 13, 1011–1022. doi: 10.1089/ars.2009.2940
Maillou, R. J. (2015). Teaching the fundamentals of electron transfer reactions in mitochondria and the production and detection of reactive oxygen species. Redox Biol. 4, 381–398. doi: 10.1016/j.redox.2015.02.001
Majzunova, M., Kvandova, M., Berenyiova, A., Balis, P., Dovinova, I., and Majzun, T., et al. (2020). C3a receptor blockade protects podocytes from injury in diabetic mice. Antioxid. Redox. Signal. 31, 1361–370. doi: 10.1089/ars.2019.60689
Migliorini, C., Perico, L., Corta, D., Locatelli, M., Cassis, P., Carminati, C. E., et al. (2020). Cfa receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight. 5:131849. doi: 10.1172/jci.insight.131849
Mukhopadhyay, P., Harvath, B., Zengeller, Z., Zielonka, J., Tanchian, G., Holovac, E., et al. (2012). Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic. Biol. Med. 52, 497–506. doi: 10.1016/j.freeradbiomed.2011.11.001
Murats, C., Bruschi, M., Candiano, G., Moroni, G., Magistroni, R., Magnano, A., et al. (2012). Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 1394–1400. doi: 10.2215/cjn.02170312
Nair, T., Weinert, B. T., and Choudhary, C. (2019). Functions and mechanisms of non-histone protein acetylation. Nat. Rev. Mol. Cell Biol. 20, 156–174. doi: 10.1038/s41580-018-0081-3
Nomiyama, T., Tanaka, Y., Piao, L., Nagasaka, K., Sakai, K., Ogihara, T., et al. (2012). Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7, 1394–1400. doi: 10.2215/cjn.02170312
Ninomiya, T., Weinert, B. T., and Choudhary, C. (2019). Functions and mechanisms of non-histone protein acetylation. Nat. Rev. Mol. Cell Biol. 20, 156–174. doi: 10.1038/s41580-018-0081-3
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., et al. (2009). Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 20, 1813–1821. doi: 10.1681/asn.2008121270
Norri, E., Nakao, A., Uchida, K., Tsukahara, H., Ohno, M., Fujita, T., et al. (2001). Oxidative and nitrosative stress in acute renal ischemia. Am. J. Physiol. Renal Physiol. 281, F948–F957.
Nomiyama, T., Tanaka, Y., Piao, L., Nagasaka, K., Sakai, K., Ogihara, T., et al. (2003). The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J. Hum. Genet. 48, 138–141.
Ogura, Y., Kitada, M., Monno, I., Kanasaki, K., Watanabe, A., and Koya, D. (2018). Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats. Redox Rep. 23, 153–159. doi: 10.1080/1351002.2018.1487174

Ogura, Y., Kitada, M., Xu, J., Monno, L., and Koya, D. (2020). CD38 inhibition by apigeninameliorates mitochondrial oxidative stress through restoration of the intracellulard NAD+/NADH ratio and Sirt3 activity in renal tubular cells in diabetic rats. Aging (Albany NY) 12, 11325–11336. doi: 10.18632/aging.103410

Onozato, M. L., Tojo, A., Goto, A., and Fujita, T. (2004). Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int. 65, 951–960. doi: 10.1111/j.1523-1755.2004.00740.x

Onozato, M. L., Tojo, A., Goto, A., Fujita, T., and Wilcox, C. S. (2002). Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 61, 186–194. doi: 10.1046/j.1523-1755.2002.00123.x

Ouyang, J., Zeng, Z., Fang, H., Li, F., Zhang, X., and Tan, W. (2019). SIRT3 inactivation promotes acute kidney injury through elevated acetylation of SOD2 and p53. J. Surg. Res. 233, 221–230. doi: 10.1016/j.jss.2019.07.019

Pani, G., Bedogni, B., Anzervino, R., Colavitti, R., Palazzotti, B., Borrello, S., et al. (2000). Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 60, 4654–4660.

Parajuli, N., Marine, A., Simmons, S., Saba, H., Mitchell, T., Shimizu, T., et al. (2011). Generation and characterization of a novel kidney-specific manganese superoxide dismutase knockout mouse. Free Radic. Biol. Med. 51, 408–416. doi: 10.1016/j.freeradbiomed.2011.04.024

Patil, N. K., Parajuli, N., MacMillan-Crow, L. A., and Mayeux, P. R. (2014). Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. Am. J. Physiol. Renal Physiol. 306, F734–F743.

Patil, N. K., Saba, H., and MacMillan-Crow, L. A. (2013). Effect of S-nitrosoglutathione on renal mitochondrial function: a new mechanism for reversible regulation of manganese superoxide dismutase activity? Free Radic. Biol. Med. 56, 54–63. doi: 10.1016/j.freeradbiomed.2012.12.001

Plotnikov, E. Y., Chupyrkina, A. A., Jankauskas, S. S., Pevzner, I. B., Silachev, D. N., Skulachev, V. P., et al. (2011). Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim. Biophys. Acta 1812, 77–86. doi: 10.1016/j.bbads.2010.09.008

Porteous, C. M., Logan, A., Evans, C., Ledgewood, E. C., Menon, D. K., Aigbirhio, F., et al. (2010). Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: implications for mitochondria-specific therapies and probes. Biochim. Biophys. Acta 1800, 1009–1017. doi: 10.1016/j.bbagenn.2010.06.001

Prumotto, M., Carnevali, M. L., Ciancardi, G., Murta, C., Bruschi, M., Corradini, E., et al. (2010). Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J. Am. Soc. Nephrol. 21, 507–519. doi: 10.1681/asn.2008121239

Qiu, X., Brown, K., Hirschy, M. D., Verdin, E., and Chen, D. (2010). Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell. 40, 893–904. doi: 10.1016/j.molcel.2010.12.013

Rao, T., Coleman, M. C., Pennington, J. D., Ozden, O., Park, S. H., Jiang, H., et al. (2010). Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell. 40, 893–904. doi: 10.1016/j.molcel.2010.12.013

Taylor, R. C., Acquaah-Mensah, G., Singhal, M., Malhotra, D., and Biswal, S. (2008). Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress. PLoS Comput. Biol. 4:e1000166. doi: 10.1371/journal.pcbi.1000166

Teissier, T., Quercis, V., Gennemi, V., Daroux, M., Howsam, M., Delgeste, F., et al. (2019). Knockout of receptor for advanced glycation end-products attenuates age-related renal lesions. Aging Cell 18, e12850. doi: 10.1111/acel.12850

Tharmalingam, S., Alhasawi, A., Appanna, V. P., Lemire, J., and Appanna, V. D. (2017). Reactive nitrogen species (RNS)-resistant microbes: adaptation and medical implications. Biol. Chem. 398, 1193–1208. doi: 10.1515/bch-2017-0152

Thuraisingham, R. C., Nott, C. A., Dodd, S. M., and Yaqoob, M. M. (2000). Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int. 57, 1968–1972. doi: 10.1046/j.1523-1755.2000.00046.x

Tian, C., Fang, S., Du, X., and Jia, C. (2011). Association of the C47T polymorphism of the CAT7 polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia 54, 803–811. doi: 10.1007/s00125-010-2004-y

Valle, I., varez-Barrientos, A., Arza, E., Lamas, S., and Monsalve, M. (2005). PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc. Res. 66, 562–573. doi: 10.1016/j.cardiores.2005.01.026

van de Ven, R. A. H., Santos, D., and Haigis, M. C. (2017). Mitochondrial sirtuins and molecular mechanisms of aging. Trends Mol. Med. 23, 320–331. doi: 10.1016/j.molmed.2017.02.005

Van Remmen, H., Ikeno, Y., Hamilton, M., Pahlavani, M., Wolf, N., Thorpe, S. R., et al. (2003). Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genom. 16, 29–37. doi: 10.1152/physiogenomics.00122.2003
Vlassara, H., Torreggiani, M., Post, J. B., Zheng, F., Urribarri, J., and Striker, G. E. (2009). Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. *Kidney Int. Suppl.* 76, S3–S11.

Walker, L. M., Walker, P. D., Imam, S. Z., Ali, S. F., and Mayeux, P. R. (2000). Evidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor L-N(6)-(1-iminoethyl)lysine. *J. Pharmacol. Exp. Ther.* 295, 417–422.

Wang, H. D., Xu, S. Q., Johns, D. G., Du, Y., Quinn, M. T., Cayatte, A. J., et al. (2001). Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. *Circ. Res.* 88, 947–953. doi: 10.1161/hh0901.089987

Wang, Y., Brancicky, R., Noé, A., and Hekimi, S. (2018). Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. *J. Cell Biol.* 217, 1915–1928. doi: 10.1083/jcb.201708007

Warner, B. B., Stuart, L., Gebb, S., and Wispé, J. R. (1996). Redox regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). *Biochem. J.* 318, 105–112. doi: 10.1042/bj3620401

Wang, Y., Branicky, R., Noë, A., and Hekimi, S. (2006). The role of MnSOD and Kidney Disease. *Kidney Int. Suppl.* 76, S3–S11.

Xiao, L., Xu, X., Zhang, F., Wang, M., Xu, Y., Tang, D., et al. (2017). The dual roles in controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* 98, 115–124. doi: 10.1016/s0092-8674(00)86811-x

Xiao, L., Xu, X., Zhang, F., Wang, M., Xu, Y., Tang, D., et al. (2017). The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. *Redox. Biol.* 11, 297–311. doi: 10.1016/j.redox.2016.12.022

Xu, J., Kitada, M., and Koya, D. (2020). The impact of mitochondrial quality control by Sirtuins on the treatment of type 2 diabetes and diabetic kidney disease. *Biochim. Biophys. Acta Mol. Basis Dis.* 1866:165756. doi: 10.1016/j.bbadis.2020.165756

Xu, S. (2016). SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. *Oxid. Med. Cell Longev.* 2016:7296092. doi: 10.1155/2016/7296092

Xu, S., Jiang, B., Maitland, K. A., Bayat, H., Gu, J., Nadler, J. L., et al. (2006). The thrombospondin receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. *Diabetes Metab. Res. Rev.* 55, 110–119. doi: 10.2337/db06-0038

Xu, Y., Kinningham, K. K., Devalaraja, M. N., Yeh, C. C., Majima, H., Kasarskis, E. J., et al. (1999). An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. *DNA Cell Biol.* 18, 709–722. doi: 10.1089/10445499314999

Xu, Y., Porntadavity, S., and St Clair, D. K. (2002). Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). *Biochem. J.* 362, 401–412. doi: 10.1042/bj3620401

Yamakura, F., and Kawasaki, H. (2010). Post-translational modifications of superoxide dismutase. *Biochim. Biophys. Acta* 1804, 318–325. doi: 10.1016/j.bbapap.2009.10.010

Yamakura, F., Taka, H., Fujimura, T., and Murayama, K. (1998). Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. *J. Biol. Chem.* 273, 14085–14089. doi: 10.1074/jbc.273.23.14085

Yamamoto, M., Clark, J. D., Pastor, J. V., Gurnani, P., Nandi, A., Kurosu, H., et al. (2005). Regulation of oxidative stress by the anti-aging hormone klotho. *J. Biol. Chem.* 280, 38029–38034. doi: 10.1074/jbc.m509039200

Yi, X., Nickelet, V., James, L. R., and Maeda, N. (2011). α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. *J. Diabetes Complicat.* 25, 193–201. doi: 10.1016/j.jdiacomp.2010.07.004

Zayed, A. E., Saleh, A., Gomaa, A. M. S., Abd-Elkareem, M., and Anwar, M. M. (2018). Protective effect of ginkgo biloba and magnetized water on nephropathy in induced type 2 diabetes in rat. *Oxid. Med. Cell Longev.* 2018:1785614. doi: 10.1155/2018/1785614

Zhang, W., Sha, Y., Wei, K., Wu, C., Ding, D., Yang, Y., et al. (2018). Rotenone ameliorates chronic renal injury caused by acute ischemia/reperfusion. *Oncotarget* 9, 24199–24208. doi: 10.18632/oncotarget.24733

Zhang, W., Yang, Y., Gao, H., Zhang, Y., Jia, Z., and Huang, S. (2019). Inhibition of mitochondrial complex i aggravates folic acid-induced acute kidney injury. *Kidney Blood Press Res.* 44, 1002–1013. doi: 10.1159/000503193

Zhao, Z., Azadzoi, K. M., Choi, H. P., Jing, R., Lu, X., Li, C., et al. (2017). LC-MS/MS analysis unravels deep oxidation of manganese superoxide dismutase in kidney cancer. *Int. J. Mol. Sci.* 18:E319. doi: 10.3390/ijms18020319

Zhu, C. H., Huang, Y., Oberley, L. W., and Domann, F. E. (2001). A family of AP-2 proteins down-regulate manganese superoxide dismutase expression. *J. Biol. Chem.* 276, 14407–14413. doi: 10.1074/jbc.201708007

Zhuang, Y., Yasinta, M., Hu, C., Zhao, M., Ding, G., Bai, M., et al. (2015). Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. *Am. J. Physiol. Renal Physiol.* 308, F857–F866.

Conflict of Interest: Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Kyowa Kirin, Taisho Pharmaceutical Co., and Ono Pharmaceutical Co., contributed to establishing the Division of Anticipatory Molecular Food Science and Technology.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kitada, Xu, Ogura, Monno and Koya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.